Safety of zotarolimus]eluting stent implantation in acute coronary syndrome patients with or without ST-elevation

Aims: to evaluate safety of zotarolimus-eluting stent (ZES) ("Endeavor Resolute") implantation in ACS patients with or without ST-elevation. A study group comprised 43 ACS patients after "Endeavor Resolute" stent implantation: 22 (51%) with ST elevation myocardial infarction (STEMI), 9 (21%) with non-STEMI, 12 (28%) had unstable angina (UA). The total number of implanted stents was 47. The mean length of a stented segment was 18.6±5.7 mm, average diameter made up 3.16±0.5 mm. All studied patients were prescribed dual antiplatelet therapy (aspirin and clopidogrel) for 12 months. Hospital and follow-up results (5.29±4 months after percutaneous coronary intervention (PCI)) were evaluated. The endpoints (MACE) were death, myocardial infarction (MI), target vessel revascularization (TVR) during hospital period and 5.29±4 months follow-up. We observed two cases of stent-thrombosis that led to recurrent MI (4.8%) and TVR (4.8%) (MACE=9.6%) during hospital period. For the STEMI patient subgroup (n=22) the frequency of inhospital stent-thrombosis and MI made up 9.1% versus 0% in the subgroups of non-STEMI and UA patients (n=21), p